The FDA issued a warning to patients and healthcare professionals to refrain from using compounded drugs distributed by Ontario, Calif.-based Fullerton Wellness, expressing concerns about the sterility of the drugs following reports of contamination.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
